A Set of Reliable Samples for the Study of Biomarkers for the Early Diagnosis of Parkinson's Disease

• Published in: Frontiers in neurology 2022-05, Vol.13, p.844841-844841
• Main Authors: Konjevod, Marcela, Sáiz, Jorge, Barbas, Coral, Bergareche, Alberto, Ardanaz, Eva, Huerta, José Ma, Vinagre-Aragón, Ana, Erro, Ma Elena, Chirlaque, Ma Dolores, Abilleira, Eunate, Ibarluzea, Jesús Ma, Amiano, Pilar
• Format: Article
• Language: English
• Subjects: biomarkers; EPIC-Navarra; fatty acids; metabolomics; Neurology; Parkinson's disease
• ISSN: 1664-2295; 1664-2295
• DOI: 10.3389/fneur.2022.844841

Parkinson's disease (PD) is a progressive neurodegenerative disorder, diagnosed according to the clinical criteria that occur in already advanced stages of PD. The definition of biomarkers for the early diagnosis of PD represents a challenge that might improve treatment and avoid complications in this disease. Therefore, we propose a set of reliable samples for the identification of altered metabolites to find potential prognostic biomarkers for early PD. This case-control study included plasma samples of 12 patients with PD and 21 control subjects, from the Spanish European Prospective Investigation into Cancer and Nutrition (EPIC)-Navarra cohort, part of the EPIC-Spain study. All the case samples were provided by healthy volunteers who were followed-up for 15.9 (±4.1) years and developed PD disease later on, after the sample collection. Liquid chromatography coupled to tandem mass spectrometry was used for the analysis of samples. Out of 40 that were selected and studied due to their involvement in established cases of PD, seven significantly different metabolites between PD cases and healthy control subjects were obtained in this study (benzoic acid, palmitic acid, oleic acid, stearic acid, myo-inositol, sorbitol, and quinolinic acid). These metabolites are related to mitochondrial dysfunction, the oxidative stress, and the mechanisms of energy production. We propose the samples from the EPIC study as reliable and invaluable samples for the search of early biomarkers of PD. Likewise, this study might also be a starting point in the establishment of a well-founded panel of metabolites that can be used for the early detection of this disease.